{
  "ticker": "LLY",
  "target_date": "2025-04-14",
  "actual_date": "2025-04-14",
  "collected_at": "2025-12-08T11:38:18.503466",
  "price": {
    "open": 746.18,
    "high": 755.24,
    "low": 730.34,
    "close": 750.0554809570312,
    "volume": 3461200,
    "change_1d_pct": 3.0,
    "change_7d_pct": -4.4,
    "change_30d_pct": -18.86
  },
  "technicals": {
    "rsi_14": 31.1,
    "sma_20": 791.26,
    "sma_50": 833.56,
    "macd": -29.611,
    "macd_signal": -23.618,
    "macd_histogram": -5.993,
    "bb_upper": 887.68,
    "bb_lower": 694.84,
    "price_vs_sma20_pct": -5.21,
    "price_vs_sma50_pct": -10.02,
    "volume_ratio": 0.93
  },
  "fundamentals": {
    "market_cap": 889332170752,
    "pe_ratio": 48.606197,
    "forward_pe": 43.7799,
    "price_to_book": 37.351376,
    "price_to_sales": 14.966933,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.79,
    "pct_from_52w_low": 59.04
  },
  "macro": {
    "spy": {
      "price": 536.04,
      "change_1d_pct": 0.97,
      "change_7d_pct": 6.7
    },
    "vix": {
      "level": 30.89,
      "signal": "HIGH_FEAR"
    },
    "treasury_10y": {
      "yield_pct": 4.36
    },
    "dollar_index": {
      "level": 99.64
    },
    "gold": {
      "price": 3204.8
    },
    "regime": "SIDEWAYS"
  },
  "news": [
    {
      "headline": "Verve\u2019s shares jump by more than 26% on Lilly-partnered gene therapy data",
      "source": "Yahoo",
      "datetime": 1744661542,
      "summary": "Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve\u2019s VERVE-101 programme.",
      "url": "https://finnhub.io/api/news?id=b04b3774780828ba81eb524510bad86c795160c4f992c96d5c2822139bb18ea3"
    },
    {
      "headline": "Eli Lilly's Mounjaro launch in India ignites wave of weight-loss enquiries",
      "source": "Yahoo",
      "datetime": 1744660158,
      "summary": "HYDERABAD (Reuters) -The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its availability, with some Indian doctors fielding hundreds of calls about the medicine, according to a Reuters survey.  The survey of 18 doctors, patients and",
      "url": "https://finnhub.io/api/news?id=450d652520858735f81a4d297f612ffc79c85e22f258a971ce30b55295ee6c58"
    },
    {
      "headline": "This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life.",
      "source": "Yahoo",
      "datetime": 1744651620,
      "summary": "A Verve Therapeutics treatment was found to cut cholesterol levels by more than half\u2014with just one shot. The stock jumped Monday.",
      "url": "https://finnhub.io/api/news?id=f4af9b21894f4d18f143b903ad8c7a970803f2b6f71894c9c2e091fbab662792"
    },
    {
      "headline": "Pharmaceutical Tariffs Coming Soon",
      "source": "Yahoo",
      "datetime": 1744650804,
      "summary": "President Trump said Monday that he is going to impose new tariffs on pharmaceuticals soon.  \u201cPharmaceuticals we\u2019re going to do,\u201d he said.  Trump has been imposing tariffs as a way to entice companies to move manufacturing to the U.S., where they would avoid import levies.",
      "url": "https://finnhub.io/api/news?id=b8e531856838dad626d87521f3ef73e305236c7d155347b93f9f0c82a7ff9602"
    },
    {
      "headline": "Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today",
      "source": "Yahoo",
      "datetime": 1744643550,
      "summary": "Pfizer bows, but is not entirely out of the GLP-1 race.",
      "url": "https://finnhub.io/api/news?id=851c58dad62e8dbbdaef0f5e04a8dfcc1947e1558ed2bdb32422f56461152881"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742416067.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000103/xslF345X05/wk-form4_1742416067.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415936.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000101/xslF345X05/wk-form4_1742415936.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415842.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000099/xslF345X05/wk-form4_1742415842.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415665.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000097/xslF345X05/wk-form4_1742415665.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415462.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000095/xslF345X05/wk-form4_1742415462.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}